Alzheimer's disease: From molecular pathogenesis to innovative therapies

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Alzheimer's disease is the most common neurodegenerative disorder and most prevalent cause of dementia in the elderly. Current standard treatment of Alzheimer's disease is based on the use of acetylcholinesterase inhibitors, which have shown symptomatic benefits on cognitive, functional and behavioral symptoms of the disease. A growing body of evidence suggests that the accumulation of amyloid β-peptides may play a pivotal role in the pathogenesis of Alzheimer's disease (amyloid hypothesis). The incremental progress in elucidating the molecular basis of Alzheimer's disease is pointing the way towards more targeted and pathogenically specific treatment approaches. This review analyzes the available data on the new directions of Alzheimer's disease therapy, with particular focus on secretase inhibitors, amyloid β-peptide vaccination, anti-inflammatory agents, metal chelators and cholesterol-lowering drugs.

Original languageEnglish
Pages (from-to)619-630
Number of pages12
JournalExpert Review of Neurotherapeutics
Volume3
Issue number5
DOIs
Publication statusPublished - Sep 2003

Fingerprint

Investigational Therapies
Alzheimer Disease
Amyloid
Behavioral Symptoms
Amyloid Precursor Protein Secretases
Neurobehavioral Manifestations
Peptides
Cholinesterase Inhibitors
Chelating Agents
Neurodegenerative Diseases
Dementia
Vaccination
Anti-Inflammatory Agents
Therapeutics
Metals
Cholesterol
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Amyloid
  • Metal chelators
  • Neuroinflammation
  • New therapies
  • Secretases
  • Statins
  • Vaccination

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Alzheimer's disease : From molecular pathogenesis to innovative therapies. / Scarpini, Elio; Cogiamanian, Filippo.

In: Expert Review of Neurotherapeutics, Vol. 3, No. 5, 09.2003, p. 619-630.

Research output: Contribution to journalArticle

@article{39c56df4ac53471d935a1cacabe99d97,
title = "Alzheimer's disease: From molecular pathogenesis to innovative therapies",
abstract = "Alzheimer's disease is the most common neurodegenerative disorder and most prevalent cause of dementia in the elderly. Current standard treatment of Alzheimer's disease is based on the use of acetylcholinesterase inhibitors, which have shown symptomatic benefits on cognitive, functional and behavioral symptoms of the disease. A growing body of evidence suggests that the accumulation of amyloid β-peptides may play a pivotal role in the pathogenesis of Alzheimer's disease (amyloid hypothesis). The incremental progress in elucidating the molecular basis of Alzheimer's disease is pointing the way towards more targeted and pathogenically specific treatment approaches. This review analyzes the available data on the new directions of Alzheimer's disease therapy, with particular focus on secretase inhibitors, amyloid β-peptide vaccination, anti-inflammatory agents, metal chelators and cholesterol-lowering drugs.",
keywords = "Alzheimer's disease, Amyloid, Metal chelators, Neuroinflammation, New therapies, Secretases, Statins, Vaccination",
author = "Elio Scarpini and Filippo Cogiamanian",
year = "2003",
month = "9",
doi = "10.1586/14737175.3.5.619",
language = "English",
volume = "3",
pages = "619--630",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Alzheimer's disease

T2 - From molecular pathogenesis to innovative therapies

AU - Scarpini, Elio

AU - Cogiamanian, Filippo

PY - 2003/9

Y1 - 2003/9

N2 - Alzheimer's disease is the most common neurodegenerative disorder and most prevalent cause of dementia in the elderly. Current standard treatment of Alzheimer's disease is based on the use of acetylcholinesterase inhibitors, which have shown symptomatic benefits on cognitive, functional and behavioral symptoms of the disease. A growing body of evidence suggests that the accumulation of amyloid β-peptides may play a pivotal role in the pathogenesis of Alzheimer's disease (amyloid hypothesis). The incremental progress in elucidating the molecular basis of Alzheimer's disease is pointing the way towards more targeted and pathogenically specific treatment approaches. This review analyzes the available data on the new directions of Alzheimer's disease therapy, with particular focus on secretase inhibitors, amyloid β-peptide vaccination, anti-inflammatory agents, metal chelators and cholesterol-lowering drugs.

AB - Alzheimer's disease is the most common neurodegenerative disorder and most prevalent cause of dementia in the elderly. Current standard treatment of Alzheimer's disease is based on the use of acetylcholinesterase inhibitors, which have shown symptomatic benefits on cognitive, functional and behavioral symptoms of the disease. A growing body of evidence suggests that the accumulation of amyloid β-peptides may play a pivotal role in the pathogenesis of Alzheimer's disease (amyloid hypothesis). The incremental progress in elucidating the molecular basis of Alzheimer's disease is pointing the way towards more targeted and pathogenically specific treatment approaches. This review analyzes the available data on the new directions of Alzheimer's disease therapy, with particular focus on secretase inhibitors, amyloid β-peptide vaccination, anti-inflammatory agents, metal chelators and cholesterol-lowering drugs.

KW - Alzheimer's disease

KW - Amyloid

KW - Metal chelators

KW - Neuroinflammation

KW - New therapies

KW - Secretases

KW - Statins

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=0041375231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041375231&partnerID=8YFLogxK

U2 - 10.1586/14737175.3.5.619

DO - 10.1586/14737175.3.5.619

M3 - Article

C2 - 19810962

AN - SCOPUS:0041375231

VL - 3

SP - 619

EP - 630

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 5

ER -